To summarize, the present study demonstrates that 1D11, a murine monoclonal TGF-β neutralizing antibody, can reverse pre-existing clinically comparable hepatic fibrosis induced by an extended dosing of TAA. Here, TGFB1 is linked to Hepatic fibrosis.